Interest of Thromboelastography (ROTEM) as a Biomarker of Revascularisation in Stroke

University Hospital, Caen64 enrolled

Overview

Revascularisation using recombinant tPA is the reference treatment of stroke. However, the efficacy of fibrinolysis is about 50%. Several factors, including the size of thrombus, have been associated with revascularisation efficacy. The aim of this prospective study is to evaluate ex vivo the effect of tPA in patients with stroke with thromboelastography and to correlate results with the clinical outcome of patients. Results may predict revascularisation in patients with stroke.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Stroke

Interventions

ThromboelastographyBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient (\> 18 years) with a neurological deficit compatible with a neurovascular pathology eligible for fibrinolysis rtPA and having a proximal occlusion of the middle cerebral artery (segment M1 / M2) or basilar trunk objectified brain imaging (MRI angiography or angio CT). Exclusion Criteria: * Any patient with major comorbidity, a pathology of hemostasis or anticoagulant treatment (vitamin K antagonist (VKA), direct oral anticoagulant).

Locations (1)

University Hospital

Caen, Calvados, France

RECRUITING

Outcomes

Primary Outcomes

Evaluation of revascularisation 24 hours after tPA injection using CT scan or MRI

Time frame: 24 hours

Secondary Outcomes

Clinical evaluation using NIHSS scale

Time frame: 24 hours

Central Contacts

Yohann REPESSE, MD PhD

CONTACT

+330231063315 repesse-y@chu-caen.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.